Arca
Skip to content

Non-small cell lung cancer - cachexia (nsclc-c)

Drug research and approvals for non-small cell lung cancer - cachexia (nsclc-c): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 0 studies of non-small cell lung cancer - cachexia (nsclc-c) are recruiting on ClinicalTrials.gov, and Health Canada has authorized 6 drug trials for it since 2013.

  • Recruiting worldwide: 0
  • Trials authorized in Canada: 6
  • FDA orphan approvals: 0
  • EU medicines: 0

Trials Authorized in Canada

Newest first; search them all in Canada trials
Jun 25, 2026An interventional, phase 1 b, double-blind, randomized, sponsor-open, 2-arm study to investigate the effect of ponsegromab on skeletal muscle mass and physical…PONSEGROMAB (PF-06946860)PfizerPending
Feb 11, 2026Rosetta lung-201: a randomized, multicenter, open-label phase 3 study of pumitamig monotherapy compared to durvalumab in participants with unresectable stage…PUMITAMIG (BMS-986545; BNT327)Bristol-Myers SquibbOngoing
Oct 10, 2025A phase 2b/3, randomized, double-blind study to investigate the efficacy, safety, and tolerability of ponsegromab (pf-06946860) compared with placebo both with…PONSEGROMAB (PF-06946860)PfizerOngoing
Feb 28, 2024A phase 3 randomized open-label study of adjuvant pembrolizumab with or without mk-2870 in participants with resectable stage ii to iiib (n2) nsclc not…MK-2870 (SKB264) / KEYTRUDAMerck & Co. (MSD)Ongoing
Nov 3, 2022A phase III, randomised, open-label, multicentre, global study of datopotamab deruxtecan (dato-dxd) in combination with durvalumab and carboplatin versus…IMFINZI / DATOPOTAMAB DERUXTECAN (DATO-DXD; DS-1062A)AstraZeneca Pharmaceuticals LPOngoing
Aug 31, 2022A phase 2a randomized, double-blind, placebo controlled multicenter study to investigate the efficacy, safety, tolerability, pharmacokinetics and…PONSEGROMAB (PF-06946860)PfizerOngoing

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.